Table 2.
Real-world studies
| Study | Disease | Study Design | Number of Eyes (Faricimab) | Number of Patients (Faricimab) | Number of Injections | Key Findings |
|---|---|---|---|---|---|---|
| TAHOE (9) | DME | Investigator-initiated real-world study | 181 | 136 | 756 | After 3 injections, mean improvement of + 3.78 letters and reduction in CST of -45.28 µm. No reported intraocular inflammation |
| FARETINA-DME (9,10) | DME | Real-world study, using IRIS registry data | 3961 | 2692 | After 4 injections, stable vision in previously treated patients and a mean improvement of 3 letters in previously untreated patients | |
| FARWIDE-DME (11) | DME | Observational, non-controlled study in the UK | 2673 | 1921 | After 4 injections, around 64% of previously treated eyes and 44% of untreated eyes achieved treatment intervals ≥ 8 weeks | |
| Rush (12) | DME | Observational, non-controlled study | 51 | 51 | Aflibercept-resistant patients switched to faricimab; 39% with a dry macula at 12 months; -0.13 logMAR improvement | |
| Kusuhara (13) | DME | Observational, non-controlled study | 21 | 19 | No statiscally signifcant improvement | |
| TRUCKEE (15, 16) | nAMD | Investigator-initiated real-world study | 2622 | 2212 | 11450 | After the first injection, mean improvement of + 1.1 letters and reduction in CST of -31.3 µm. Two cases of idiopathic ocular inflammation reported |
| FARETINA-nAMD (17) | nAMD | Real-world study, using IRIS registry data | 12.119 | 10551 | After 4 injections, mean improvement of 0.5 letters in previously treated patients and 1.6 letters in untreated patients | |
| FARWIDE-nAMD (18) | nAMD | Observational, non-controlled study in the UK | 3564 | 2987 | ||
| Rush and Rush (19) | nAMD | Case-control study | 27 | Comparison with aflibercept. Higher improvement in the switch group from aflibercept to faricimab | ||
| Leung (20) | nAMD | Observational, non-controlled study in Atlanta, GA | 190 | After 3 injections, -0.06 logMAR improvement and − 25 µm CST reduction | ||
| Mukai (21) | nAMD | Observational, non-controlled study in Japan | 63 | 61 | 82% of the eyes achieved a dry macula at month 3 | |
| Matsumoto (22) | nAMD | Observational, non-controlled study in Japan | 40 | 38 | LogMAR improvement of -0.11; dry macula in 79.5%; and complete polupoidal resolution in 61.1% of the eyes | |
| Cheng (24) | nAMD | Observational, non-controlled study | 13 | |||
| Stanga (23) | nAMD | Observational, non-controlled study | 11 |